Edgen Stock·Dec 13 2025, 09:46Back
Arcus Halts TIGIT Program After Trial Failure
Edgen Stock·Dec 13 2025, 09:46
[1] ‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure - BioSpace (https://www.biospace.com/drug-development/au- ...)[2] Arcus halts Gilead-partnered TIGIT trials as biotech reworks R&D focus - Fierce Biotech (https://www.fiercebiotech.com/biotech/arcus-h ...)[3] Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants - BioSpace (https://www.biospace.com/press-releases/anixa ...)
